Next-Gen mAb Oncology eBook
Last updated: July 2024
Monoclonal antibodies (mAbs) have revolutionized targeted cancer therapies with unmatched specificity and potency. Since the first mAb approval in 1986, advancements like refining hybridoma technology and the advent of phage display have significantly improved mAb efficacy and streamlined cell line development and molecule characterization. This progress has paved the way for next-generation antibody-based therapeutics.
Antibody-drug conjugates (ADCs) and bispecific antibodies (bsAbs) mark significant advances in precision medicine. BsAbs, with dual-targeting capabilities, have shown therapeutic potential beyond traditional mAbs, with nine novel bsAbs securing regulatory nods for oncology indications. ADCs such as Enhertu® combine the targeting power of mAbs with cytotoxic drugs' cell-killing force, offering "precision chemotherapy" that is projected to reach $9 billion in sales by 2028.
This ebook highlights Sartorius’ high-throughput instruments' role in developing next-generation therapies.
Complete the Form to Access the eBook
Figure 1. Table of Contents.
Please select your country so we can show you products that are available for you.
The content of our website is always available in English and partly in other languages. Choose your preferred language and we will show you the content in that language, if available.